HCA Holdings price target raised to $74 from $62 at Oppenheimer Oppenheimer increased its price target on HCA after the company reported Q2 EPS that was in-line with its preannouncement but well ahead of prior Street estimates. The firm raised its estimates based on the company's guidance and keeps an Outperform rating on the shares.
HCA Holdings reported strong Q1 results, says RBC Capital After HCA Holdings reported stronger than expected Q1 results, RBC Capital says it was particularly encouraged that the company raised its guidance by more than the amount by which its earnings beat guidance. The firm says this indicates that the company has strong confidence in the sustainability of its underlying trends. RBC keeps an Outperform rating on the shares.
HCA Holdings raises FY15 adjusted EPS view to $4.90-$5.30 from $4.55-$4.95 Consensus is $4.93. Raises FY15 revenue view to $39B-$40B from $38.5B-$39.5B. Raises FY adjusted EBITDA view to $7.55B-$7.85B from $7.35B-$7.65B. Still sees FY CapEx approx. $2.4B. The Company’s revised 2015 guidance contains a number of assumptions that remain unchanged from its February 2015 guidance, including: The Company estimates approximately 6 to 7 percent of Adjusted EBITDA is attributable to the Patient Protection and Affordable Care Act.